Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer Clinical Trial

Official title:

Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00126568
• Other study ID #: NCI-2009-00118
• Secondary ID: NCI-2009-00118CA
• Status: Terminated
• Phase: Phase 2
• First received: August 2, 2005
• Last updated: December 20, 2017
• Start date: June 2005
• Est. completion date: September 2011

Study information

• Verified date: December 2017
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Description:

OBJECTIVES:

I. Determine whether the objective response rate is ≥ 20% in patients with advanced anaplastic thyroid cancer treated with sorafenib.

II. Determine the survival of patients treated with this drug. III. Determine the safety profile of this drug in these patients. IV. Determine the pharmacokinetic predictors of response to this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for survival.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Criteria:

• Progressive disease after prior cytotoxic chemotherapy (i.e., chemotherapy alone or combined with radiotherapy)

• No symptomatic bulky disease that would impair the airway or impede swallowing (for patients with ECOG performance status 2)

• No known brain metastases

• Measurable or evaluable disease

• Measurable disease, defined as = 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

• Measurable disease not in a previously irradiated field

• Patients with evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) are eligible provided disease has been stable for the past 6 months

• Performance status:

• ECOG 0-2 OR Karnofsky 50-100%

• Life expectancy more than 8 weeks

• Absolute neutrophil count >= 1,250/mm3

• Platelet count >= 100,000/mm3

• No evidence of bleeding diathesis

• Bilirubin =< 1.5 times upper limit of normal (ULN)

• PTT =< 1.5 times ULN

• Creatinine =< 1.5 times ULN

• No myocardial infarction within the past 6 months

• No New York Heart Association class III or IV cardiac disease

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No uncontrolled hypertension (i.e., systolic blood pressure (BP) > 150 mm Hg OR diastolic BP > 100 mm Hg)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Able to swallow oral medication

• No history of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study compliance

• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

• No other uncontrolled illness

• No more than 2 prior systemic cytotoxic chemotherapy regimens (combined modality systemic cytoxic chemotherapy is considered 1 prior cytotoxic regimen)

• At least 7 days since prior chemotherapy and recovered

• At least 7 days since prior radiotherapy and recovered

• No prior sorafenib or other inhibitors of MAP kinase signaling intermediates

• No prior cancer treatment that would preclude study participation

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No other concurrent investigational agents

• No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)

• No concurrent Hypericum perforatum (St. John's wort) or rifampin

• No concurrent therapeutic anticoagulation (concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided requirements for INR and PTT are met)

• No other concurrent anticancer therapy

• Histologically confirmed anaplastic* thyroid cancer

• Not amenable to definitive curative surgery or radiotherapy [Note: *Papillary, follicular, or other histologies that are mixed or identified in a diagnostic tissue sample are allowed provided a high-grade undifferentiated anaplastic component is present ]

• No cardiac arrhythmia

• AST and ALT =< 3.5 times ULN

• INR < 2.0

Related Conditions & MeSH terms

• Anaplastic Thyroid Cancer
• Recurrent Thyroid Cancer
• Thyroid Carcinoma, Anaplastic
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Drug:
• sorafenib tosylate
Given orally

Locations

Country	Name	City	State
United States	Case Western Reserve University	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Response to Treatment Measured by RECIST Criteria	Response evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. The patient's best response depends on the achievement of measurement and confirmation criteria of Complete Response (CR), Stable Disease (SD), Partial Response (PR) or Progressive Disease (PD). Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, x-ray) or as >10 mm with spiral CT scan.	at 6 months after treatment
Secondary	Progression Free Survival Was Measured From the Date of Outset of Treatment to the Date of Disease Progression.		27 months
Secondary	Overall Survival Was Measured From the Date of Outset of Treatment to the Date of Death.		27 months
Secondary	Number of Participants That Experienced Adverse Events to Characterize the Safety Profile of BAY 43-9006	The safety and toxicity profile of BAY 43-9006 as measured by toxicity grades of adverse events.	27 months